膜杰作
Star Staining
- Genetically modified cell lines best reflect MOA (Mechanism of Action)
- Higher activity and larger assay window for robust and reproducible cell-based bioassay
- Comprehensive application data to support assay development and validation
- Full tracible record, stringent quality control and validated cell passage stability
- Parental cell line legally obtained from internationally recognized cell resource bank and commercially licensed
- Global commercial license assistance whenever regulatory filing is required
描述（Description）
The Human IL-23 R/IL-12 R beta 1 (Luc) HEK293 Reporter Cell was engineered to not only express STAT3 signaling response element, but also express the receptors full length human IL-23 R (Gene ID:149233) and IL-12 R beta 1 (Gene ID:3594). When stimulated with human IL-23 protein, receptor-mediated signaling can drive STAT3-mediated luminescence. Neutralization of biological effect of the ligand-receptor interaction by corresponding antibody results in a decrease in luminescence.
应用说明（Application）
•Screen for anti-human IL-23 neutralizing antibody.
生长特性（Growth Properties）
Adherent
筛选标记（Selection Marker）
Puromycin (2 μg/mL) + Zeocin (20 μg/mL)
培养基（Culture Medium）
DMEM + 10% FBS
冻存液（Freeze Medium）
Serum-free cell cryopreservation medium
装量（Quantity）
1 vial contains at least 5×10^6 cells in 1 mL serum-free cryopreservation medium
存储（Storage）
Frozen in liquid nitrogen.
支原体检测（Mycoplasma Testing）
Negative
无菌检测（Sterility Testing）
Negative
使用说明（Instructions for Use）
See data sheet for detailed culturing and assay protocol.
Receptor Assay
Co-expression analysis of human IL-23 R and IL-12 R beta 1 on Human IL-23 R/IL-12 R beta 1 (Luc) HEK293 Reporter Cell by FACS.
Cell surface staining was performed on Human IL-23 R/IL-12 R beta 1 (Luc) HEK293 Reporter Cell or negative control cell using PE-labeled anti-IL-23 R antibody and APC-labeled anti-IL-12 R beta 1 antibody.
Protocol
Application
Inhibition of human IL-23 protein-induced reporter activity by anti-human IL-23 neutralizing antibody.
This reporter cell was incubated with serial dilutions of antibodies in the presence of human IL-23 protein (Cat. No. ILB-H52W5) with a final concentration of 0.1 μg/mL. The EC50 of Ustekinumab is approximately 0.08049 μg/mL, and the EC50 of Guselkumab is approximately 0.05874 μg/mL.
Protocol
Signaling Bioassay
Response to human IL-23 protein (RLU).
The Human IL-23 R/IL-12 R beta 1 (Luc) HEK293 Reporter Cell was stimulated with serial dilutions of human IL-23 protein (Cat. No. ILB-H52W5). The EC50 was approximately 0.3826 μg/mL.
Protocol
Response to human IL-23 protein (FOLD).
The Human IL-23 R/IL-12 R beta 1 (Luc) HEK293 Reporter Cell was stimulated with serial dilutions of human IL-23 protein (Cat. No. ILB-H52W5). The max induction fold was approximately 194.
Protocol
如有相关细胞池需求请联系我们
背景（Background）
IL-23 is a heterodimeric cytokine composed of p40 and p19 subunits. It binds to its IL-23 receptor complex composed of IL-12RB1 and IL-23R subunits, which are associated with the Jak family members, Tyk2 and Jak2, respectively. IL-23 binding to its receptor complex results in Jak2-mediated phosphorylation of tyrosine residues located in the intracellular domain of the IL-23R subunit. Phosphorylated tyrosine residues serve as a docking site for STAT3 molecules, which in turn get phosphorylated. Phospho-STAT3 proteins homodimerize and translocate into the nucleus inducing transcription of cytokines, such as IL-17A, IL-17F, IL-22 and IFN-.
Limited Use&License Disclosure
- This cell line is provided for research use only. It is neither intended for any animal or human therapeutic use nor for any direct human in vivo use. You are restricted to share, modify, transfer, distribute, sell, sublicense, or otherwise make the cell line available for use to other researchers, laboratories, research institutions, hospitals, universities, or service organizations.
- ACROBIOSYSTEMS MAKES NO WARRANTIES OR REPRESENTATIONS OF ANY KIND, EITHER EXPRESSED OR IMPLIED, WITH RESPECT TO THE SUITABILITY OF THE CELL LINE FOR ANY PARTICULAR USE.
- ACROBIOSYSTEMS ACCEPTS NO LIABILITY IN CONNECTION WITH THE HANDLING OR USE OF THE CELL LINE.
- Modifications of the cell line, transfer to a third party, or commercial use of the cell line may require a separate license and additional fees. Please contact order.cn@acrobiosystems.com for further details.
